Novartis AG

Novartis AG is a Swiss multinational pharmaceutical corporation headquartered in Basel, one of the world's largest manufacturers of innovative medicines. Formed in 1996 through the historic merger of Ciba-Geigy and Sandoz, it originated from pioneering Swiss chemical firms dating back to the late 19th century, known for breakthroughs like DDT's insecticidal properties and early pharmaceuticals. In 2023, Novartis restructured by spinning off its generics division, Sandoz, to concentrate on the Innovative Medicines division, focusing on cutting-edge therapeutic areas including oncology, immunology, cardiovascular-renal-metabolic diseases, neuroscience, rare diseases, and ophthalmology. The company employs advanced modalities such as biotherapeutics, gene and cell therapies, radioligand therapy, and xRNA therapeutics, with a robust pipeline featuring late-stage programs and partnerships in AI-driven drug discovery and molecular glues. Novartis operates in approximately 140 countries, reaching millions of patients with key products like Gleevec for leukemia, Entresto for heart failure, Cosentyx for psoriasis, and Kymriah for leukemia via CAR-T therapy. Through its Novartis Institutes for BioMedical Research, it drives global R&D efforts, significantly influencing the pharmaceutical industry's innovation landscape.